Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm
For more than a century, the high occurrences of coronary and peripheral artery diseases in diabetes mellitus patients has been well recognised; despite that, the ability to improve CV event rates by optimizing glycaemic control has remained elusive. Nevertheless, the last decade has seen several ca...
Gespeichert in:
| Veröffentlicht in: | Diabetes & metabolic syndrome clinical research & reviews 2019-05, Vol.13 (3), p.1935-1942 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1942 |
|---|---|
| container_issue | 3 |
| container_start_page | 1935 |
| container_title | Diabetes & metabolic syndrome clinical research & reviews |
| container_volume | 13 |
| creator | Bin Hussain, Azza Khalifa Abdelgadir, Elamin Rashid, Fauzia Al Haj, Abeer Thadani, Puja Bashier, Alaaeldin M.K. |
| description | For more than a century, the high occurrences of coronary and peripheral artery diseases in diabetes mellitus patients has been well recognised; despite that, the ability to improve CV event rates by optimizing glycaemic control has remained elusive. Nevertheless, the last decade has seen several cardiovascular outcome clinical trials (CVOTs) of many antihyperglycemic agents that reported promising results for cardiovascular and renal outcomes. This leads to a hot debate on the ideal drug choice for first-line treatment in T2DM. The purpose of this paper is to review the evidence supporting the use of metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors and incretin-based therapies for the management of individuals with T2DM and, discuss the rationale for selection. |
| doi_str_mv | 10.1016/j.dsx.2019.04.028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2246908091</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1871402119302218</els_id><sourcerecordid>2246908091</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-f7e4fb81925b1cda5a25e4428904e98e934f3c37676df043ead0c757dbf2a38d3</originalsourceid><addsrcrecordid>eNp9kLtu3DAQRYkgRvzKB7gxWKaRwpdWJFIEhuHEAQy4SFwTFDnc5UISNyTlR-k_N511UqaaKc69mDkInVHSUkJXn7ety48tI1S1RLSEyXfoiMpeNoRz8f7PThtBGD1ExzlvCek6xdQHdMgp4x2l8gg9_9zEZXR4guJjmsKMcwnjiAfAZQPYh5RLM4YZcPS4JDBlgrngypWnHWCGXTADFMi1YRxDWfJXfIFtnHYJNjDncA84wX2AB2xmh_OyXkMu4LAZ1zGFsplO0YE3Y4aPb_ME3X27-nV53dzcfv9xeXHTWN7x0vgehB8kVawbqHWmM6wDIZhURICSoLjw3PJ-1a-cJ4KDccT2Xe8GzwyXjp-gT_veXYq_l3qEnkK29WgzQ1yyZkysFJFE0YrSPWpTzDmB17sUJpOeNCX61bze6mpev5rXROhqvmbO3-qXYQL3L_FXdQW-7AGoT1YhSWcbYLbgQgJbtIvhP_UvWbaWNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2246908091</pqid></control><display><type>article</type><title>Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bin Hussain, Azza Khalifa ; Abdelgadir, Elamin ; Rashid, Fauzia ; Al Haj, Abeer ; Thadani, Puja ; Bashier, Alaaeldin M.K.</creator><creatorcontrib>Bin Hussain, Azza Khalifa ; Abdelgadir, Elamin ; Rashid, Fauzia ; Al Haj, Abeer ; Thadani, Puja ; Bashier, Alaaeldin M.K.</creatorcontrib><description>For more than a century, the high occurrences of coronary and peripheral artery diseases in diabetes mellitus patients has been well recognised; despite that, the ability to improve CV event rates by optimizing glycaemic control has remained elusive. Nevertheless, the last decade has seen several cardiovascular outcome clinical trials (CVOTs) of many antihyperglycemic agents that reported promising results for cardiovascular and renal outcomes. This leads to a hot debate on the ideal drug choice for first-line treatment in T2DM. The purpose of this paper is to review the evidence supporting the use of metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors and incretin-based therapies for the management of individuals with T2DM and, discuss the rationale for selection.</description><identifier>ISSN: 1871-4021</identifier><identifier>EISSN: 1878-0334</identifier><identifier>DOI: 10.1016/j.dsx.2019.04.028</identifier><identifier>PMID: 31235118</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Algorithms ; Blood Glucose - analysis ; Diabetes Mellitus, Type 2 - drug therapy ; Humans ; Hypoglycemic Agents - therapeutic use ; Metformin - therapeutic use ; Prognosis ; Risk Factors</subject><ispartof>Diabetes & metabolic syndrome clinical research & reviews, 2019-05, Vol.13 (3), p.1935-1942</ispartof><rights>2019 Diabetes India</rights><rights>Copyright © 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-f7e4fb81925b1cda5a25e4428904e98e934f3c37676df043ead0c757dbf2a38d3</citedby><cites>FETCH-LOGICAL-c353t-f7e4fb81925b1cda5a25e4428904e98e934f3c37676df043ead0c757dbf2a38d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1871402119302218$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31235118$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bin Hussain, Azza Khalifa</creatorcontrib><creatorcontrib>Abdelgadir, Elamin</creatorcontrib><creatorcontrib>Rashid, Fauzia</creatorcontrib><creatorcontrib>Al Haj, Abeer</creatorcontrib><creatorcontrib>Thadani, Puja</creatorcontrib><creatorcontrib>Bashier, Alaaeldin M.K.</creatorcontrib><title>Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm</title><title>Diabetes & metabolic syndrome clinical research & reviews</title><addtitle>Diabetes Metab Syndr</addtitle><description>For more than a century, the high occurrences of coronary and peripheral artery diseases in diabetes mellitus patients has been well recognised; despite that, the ability to improve CV event rates by optimizing glycaemic control has remained elusive. Nevertheless, the last decade has seen several cardiovascular outcome clinical trials (CVOTs) of many antihyperglycemic agents that reported promising results for cardiovascular and renal outcomes. This leads to a hot debate on the ideal drug choice for first-line treatment in T2DM. The purpose of this paper is to review the evidence supporting the use of metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors and incretin-based therapies for the management of individuals with T2DM and, discuss the rationale for selection.</description><subject>Algorithms</subject><subject>Blood Glucose - analysis</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Metformin - therapeutic use</subject><subject>Prognosis</subject><subject>Risk Factors</subject><issn>1871-4021</issn><issn>1878-0334</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kLtu3DAQRYkgRvzKB7gxWKaRwpdWJFIEhuHEAQy4SFwTFDnc5UISNyTlR-k_N511UqaaKc69mDkInVHSUkJXn7ety48tI1S1RLSEyXfoiMpeNoRz8f7PThtBGD1ExzlvCek6xdQHdMgp4x2l8gg9_9zEZXR4guJjmsKMcwnjiAfAZQPYh5RLM4YZcPS4JDBlgrngypWnHWCGXTADFMi1YRxDWfJXfIFtnHYJNjDncA84wX2AB2xmh_OyXkMu4LAZ1zGFsplO0YE3Y4aPb_ME3X27-nV53dzcfv9xeXHTWN7x0vgehB8kVawbqHWmM6wDIZhURICSoLjw3PJ-1a-cJ4KDccT2Xe8GzwyXjp-gT_veXYq_l3qEnkK29WgzQ1yyZkysFJFE0YrSPWpTzDmB17sUJpOeNCX61bze6mpev5rXROhqvmbO3-qXYQL3L_FXdQW-7AGoT1YhSWcbYLbgQgJbtIvhP_UvWbaWNQ</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>Bin Hussain, Azza Khalifa</creator><creator>Abdelgadir, Elamin</creator><creator>Rashid, Fauzia</creator><creator>Al Haj, Abeer</creator><creator>Thadani, Puja</creator><creator>Bashier, Alaaeldin M.K.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201905</creationdate><title>Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm</title><author>Bin Hussain, Azza Khalifa ; Abdelgadir, Elamin ; Rashid, Fauzia ; Al Haj, Abeer ; Thadani, Puja ; Bashier, Alaaeldin M.K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-f7e4fb81925b1cda5a25e4428904e98e934f3c37676df043ead0c757dbf2a38d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Algorithms</topic><topic>Blood Glucose - analysis</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Metformin - therapeutic use</topic><topic>Prognosis</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bin Hussain, Azza Khalifa</creatorcontrib><creatorcontrib>Abdelgadir, Elamin</creatorcontrib><creatorcontrib>Rashid, Fauzia</creatorcontrib><creatorcontrib>Al Haj, Abeer</creatorcontrib><creatorcontrib>Thadani, Puja</creatorcontrib><creatorcontrib>Bashier, Alaaeldin M.K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes & metabolic syndrome clinical research & reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bin Hussain, Azza Khalifa</au><au>Abdelgadir, Elamin</au><au>Rashid, Fauzia</au><au>Al Haj, Abeer</au><au>Thadani, Puja</au><au>Bashier, Alaaeldin M.K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm</atitle><jtitle>Diabetes & metabolic syndrome clinical research & reviews</jtitle><addtitle>Diabetes Metab Syndr</addtitle><date>2019-05</date><risdate>2019</risdate><volume>13</volume><issue>3</issue><spage>1935</spage><epage>1942</epage><pages>1935-1942</pages><issn>1871-4021</issn><eissn>1878-0334</eissn><abstract>For more than a century, the high occurrences of coronary and peripheral artery diseases in diabetes mellitus patients has been well recognised; despite that, the ability to improve CV event rates by optimizing glycaemic control has remained elusive. Nevertheless, the last decade has seen several cardiovascular outcome clinical trials (CVOTs) of many antihyperglycemic agents that reported promising results for cardiovascular and renal outcomes. This leads to a hot debate on the ideal drug choice for first-line treatment in T2DM. The purpose of this paper is to review the evidence supporting the use of metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors and incretin-based therapies for the management of individuals with T2DM and, discuss the rationale for selection.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>31235118</pmid><doi>10.1016/j.dsx.2019.04.028</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1871-4021 |
| ispartof | Diabetes & metabolic syndrome clinical research & reviews, 2019-05, Vol.13 (3), p.1935-1942 |
| issn | 1871-4021 1878-0334 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2246908091 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Algorithms Blood Glucose - analysis Diabetes Mellitus, Type 2 - drug therapy Humans Hypoglycemic Agents - therapeutic use Metformin - therapeutic use Prognosis Risk Factors |
| title | Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T02%3A41%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Should%20metformin%20still%20be%20the%20first-line%20of%20treatment%20in%20type%202%20diabetes%20mellitus?%20A%20comprehensive%20review%20and%20suggested%20algorithm&rft.jtitle=Diabetes%20&%20metabolic%20syndrome%20clinical%20research%20&%20reviews&rft.au=Bin%20Hussain,%20Azza%20Khalifa&rft.date=2019-05&rft.volume=13&rft.issue=3&rft.spage=1935&rft.epage=1942&rft.pages=1935-1942&rft.issn=1871-4021&rft.eissn=1878-0334&rft_id=info:doi/10.1016/j.dsx.2019.04.028&rft_dat=%3Cproquest_cross%3E2246908091%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2246908091&rft_id=info:pmid/31235118&rft_els_id=S1871402119302218&rfr_iscdi=true |